CN109096358B - 3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 - Google Patents
3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109096358B CN109096358B CN201811108808.6A CN201811108808A CN109096358B CN 109096358 B CN109096358 B CN 109096358B CN 201811108808 A CN201811108808 A CN 201811108808A CN 109096358 B CN109096358 B CN 109096358B
- Authority
- CN
- China
- Prior art keywords
- solution
- parts
- biotin
- reaction
- crude product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 239000011616 biotin Substances 0.000 title claims abstract description 33
- 229960002685 biotin Drugs 0.000 title claims abstract description 33
- -1 benzimidazole compound Chemical class 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 15
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- 239000000543 intermediate Substances 0.000 claims description 59
- 238000006243 chemical reaction Methods 0.000 claims description 53
- 239000012043 crude product Substances 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 36
- 238000004809 thin layer chromatography Methods 0.000 claims description 34
- 238000004440 column chromatography Methods 0.000 claims description 30
- 238000000926 separation method Methods 0.000 claims description 28
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003480 eluent Substances 0.000 claims description 17
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 238000004821 distillation Methods 0.000 claims description 14
- 239000003208 petroleum Substances 0.000 claims description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 11
- 235000000638 D-biotin Nutrition 0.000 claims description 8
- 239000011665 D-biotin Substances 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000000967 suction filtration Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 22
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 5
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 5
- 201000010881 cervical cancer Diseases 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002900 effect on cell Effects 0.000 abstract description 2
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 63
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
- 210000001985 kidney epithelial cell Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000006385 ozonation reaction Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004987 o-phenylenediamines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
细胞株类型 | HeLa | SKOV-3 | T47D | HEK293T |
实施例1 | 24.1±3.7 | 16.8±3.8 | 6.8±3.9 | >200 |
实施例2 | 18.9±2.4 | 19.7±1.7 | 22.4±2.1 | >200 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811108808.6A CN109096358B (zh) | 2018-09-21 | 2018-09-21 | 3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811108808.6A CN109096358B (zh) | 2018-09-21 | 2018-09-21 | 3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109096358A CN109096358A (zh) | 2018-12-28 |
CN109096358B true CN109096358B (zh) | 2021-11-26 |
Family
ID=64867171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811108808.6A Active CN109096358B (zh) | 2018-09-21 | 2018-09-21 | 3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109096358B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104447937A (zh) * | 2014-12-17 | 2015-03-25 | 广西师范学院 | 一种b-降胆甾烷苯并咪唑类化合物及其制备方法和用途 |
WO2016181312A1 (en) * | 2015-05-11 | 2016-11-17 | Versitech Limited | Polycyclic epoxides and compositions thereof with anti-cancer activities |
CN106866772A (zh) * | 2017-01-11 | 2017-06-20 | 武汉大学 | 一种胆固醇分子探针及其制备方法和应用 |
CN107383150A (zh) * | 2017-07-19 | 2017-11-24 | 佛山市第五人民医院 | 一种具有抗肝损伤活性的化合物及其制备方法和用途 |
-
2018
- 2018-09-21 CN CN201811108808.6A patent/CN109096358B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104447937A (zh) * | 2014-12-17 | 2015-03-25 | 广西师范学院 | 一种b-降胆甾烷苯并咪唑类化合物及其制备方法和用途 |
WO2016181312A1 (en) * | 2015-05-11 | 2016-11-17 | Versitech Limited | Polycyclic epoxides and compositions thereof with anti-cancer activities |
CN106866772A (zh) * | 2017-01-11 | 2017-06-20 | 武汉大学 | 一种胆固醇分子探针及其制备方法和应用 |
CN107383150A (zh) * | 2017-07-19 | 2017-11-24 | 佛山市第五人民医院 | 一种具有抗肝损伤活性的化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109096358A (zh) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents | |
Lei et al. | Synthesis and biological evaluation of bufalin-3-yl nitrogen-containing-carbamate derivatives as anticancer agents | |
CN109134586A (zh) | 雷公藤红素衍生物及其应用 | |
Yang et al. | Isostructurality among 5 solvatomorphs of betulin: X-Ray structure and characterization | |
WO2015096640A1 (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
CN109096358B (zh) | 3-生物素醚酯-b降-胆甾苯并咪唑化合物及其制备方法和应用 | |
CN105061397A (zh) | 一种色瑞替尼的c型晶型及其制备方法与应用 | |
WO2020062883A1 (zh) | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 | |
Kiss et al. | Stereocontrolled synthesis of the four possible 3-methoxy and 3-benzyloxy-16-triazolyl-methyl-estra-17-ol hybrids and their antiproliferative activities | |
CN104447937A (zh) | 一种b-降胆甾烷苯并咪唑类化合物及其制备方法和用途 | |
CN109206399B (zh) | 三级酰胺微管蛋白聚合抑制剂及其制备方法和应用 | |
Fan et al. | Synthesis of novel 4′-acylamino modified 21E-benzylidene steroidal derivatives and their cytotoxic activities | |
Zhou et al. | Design, synthesis and anti-tumor activities of carbamate derivatives of cinobufagin | |
CN115043826A (zh) | 一类青藤碱呋咱衍生物及其制备方法和应用 | |
CN106397408A (zh) | 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途 | |
CN113061124B (zh) | 倍半萜二聚体化合物及其制备方法、应用和药物组合物 | |
CN111333495B (zh) | (4-甲氧基-3-羟基苯基)(3,5-二甲基-2-羟基苯基)甲酮及制备方法和应用 | |
CN110041239B (zh) | N-(苯甲酰基)-l-半胱氨酸甲酯类衍生物及其制备方法和用途 | |
CN109251224B (zh) | 同时具有化疗和光疗抗肿瘤作用的铱配合物及其制备方法和应用 | |
CN109232570B (zh) | 一种含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
WO2010134830A1 (en) | Triterpenoid derivatives useful as antiproliferative agents | |
Kiss et al. | Stereoselective synthesis of new type of estradiol hybrid molecules and their antiproliferative activities | |
CN108125962B (zh) | 苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 | |
CN114874135B (zh) | 一类抗乳腺癌的小分子化合物及其制备方法 | |
CN111087302B (zh) | 布洛芬阿魏酸酯的合成方法及其在制备免疫抑制药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 175, Mingxiu East Road, Nanning City, Guangxi Zhuang Autonomous Region Patentee after: NANNING NORMAL University Address before: No.3 Hexing Road, Qingxiu District, Nanning City, Guangxi Zhuang Autonomous Region Patentee before: Guangxi Normal University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231008 Address after: 215000 East 9th Floor, Entrepreneurship Center, Science and Technology Entrepreneurship Park, No. 6 Beijing West Road, Taicang City, Suzhou City, Jiangsu Province Patentee after: Suzhou Ruifeng pharmaceutical R & D Co.,Ltd. Address before: No. 175, Mingxiu East Road, Nanning City, Guangxi Zhuang Autonomous Region Patentee before: NANNING NORMAL University |